Volume 10, Issue 40 (8-2020)                   NCMBJ 2020, 10(40): 91-102 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

jafari hafshejani R, gheibi hajivar F, nikkhah S. Effect of Silymarin on Blood Glucose and Hnf1a Gene Expression in Streptozotocin-Induced Diabetic Male Wistar Rats. NCMBJ. 2020; 10 (40) :91-102
URL: http://ncmbjpiau.ir/article-1-1320-en.html
Department of Biology, Science Faculty, Islamic Azad University, Shahrekord Branch, Shahrekord, Iran
Abstract:   (1073 Views)
Aim and Background: Today, research has shown that medicinal plants have fewer side effects than industrial and chemical judges. On the other hand, studies indicate the important role of Hnf1a gene in diabetes, so the aim of this study was to investigate the effect of silymarin on blood sugar and expression of Hnf1a gene in male Wistar rats diabetic with streptozoto.
Material and methods:  42 male rats were randomly selected and divided into seven groups. Sixty diabetic rats with diabetic streptozotocin have been measured and their fasting blood glucose was measured. After the end of the period, the rats were anesthetized with the drug. A portion of the pancreatic tissue was isolated and used to evaluate the expression of Hnf1a gene using Real Time RT PCR..
Results: Evaluation of Hnf1alpha at a dose of 150 mg / kg in silymarin-receiving rats showed a significant decrease in Hnf1alpha gene expression and was introduced as an effective dose (P-Value <0.05) due to the use of silymarin in the country. It is not common, in future research, more importance can be given to the effects of silymarin and it can be considered as an effective drug.
Conclusion: Based on the results of this study, it can be concluded that silymarin reduces blood sugar in diabetes and, if confirmed in extensive studies, can be considered as a therapeutic target in diabetes.
Full-Text [PDF 5216 kb]   (210 Downloads) |   |   Full-Text (HTML)  (366 Views)  
Type of Study: Research Article | Subject: Cellular and molecular
Received: 2020/10/21 | Accepted: 2020/08/31 | Published: 2020/08/31

1. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An expanded genome-wide association study of type 2 diabetes in Europeans. Diabetes. 2017:db161253.
2. Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;66(2):241-55.
3. Volkov P, Bacos K, Ofori JK, Esguerra JLS, Eliasson L, Rönn T, et al. Whole-genome bisulfite sequencing of human pancreatic islets reveals novel differentially methylated regions in type 2 diabetes pathogenesis. Diabetes. 2017:db160996.
4. Wang Q, Zhang M, Torres G, Wu S, Ouyang C, Xie Z, et al. Metformin suppresses diabetes-accelerated atherosclerosis via the inhibition of Drp1-mediated mitochondrial fission. Diabetes. 2017;66(1):193-205.
5. Association AD. 15. Diabetes Advocacy: Standards of Medical Care in Diabetes-2018. Diabetes care. 2018;41(Suppl 1):S152.
6. Tripathi BK, Srivastava AK. Diabetes mellitus: Complications and therapeutics. Medical Science Monitor. 2006;12(7):RA130-RA47.
7. Gatreh-Samani K, Farrokhi E, Khalili B, Rafieian-Kopaei M, Moradi M. Purslane (Portulaca oleracea) effects on serum paraoxanase-1 activity. Journal of Shahrekord Uuniversity of Medical Sciences. 2011;13.
8. Suji G, Sivakami S. Approaches to the treatement of diabetes mellitus: an overview. Cellular and molecular biology (Noisy-le-Grand, France). 2003;49(4):635-9.
9. Topaloğlu Ö, Evren B, Şahin İ. Monogenic Diabetes Case Presented with Symptomatic Hyperglycemia and Atypical Mutation. Journal of Clinical Research in Pediatric Endocrinology. 2017;9(1):14.
10. Iacovazzo D, Flanagan SE, Walker E, Quezado R, de Sousa Barros FA, Caswell R, et al. MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proceedings of the National Academy of Sciences. 2018:201712262.
11. López‐Noriega L, Cobo‐Vuilleumier N, Narbona‐Pérez ÁJ, Araujo‐Garrido JL, Lorenzo PI, Mellado‐Gil JM, et al. Levothyroxine enhances glucose clearance and blunts the onset of experimental type 1 diabetes mellitus in mice. British journal of pharmacology. 2017;174(21):3795-810.
12. Stueck AE, Qu Z, Huang MAY, Campreciós G, Ferrell LD, Thung SN, editors. Hepatocellular Carcinoma Arising in an HNF-1α–Mutated Adenoma in a 23-Year-Old Woman with Maturity-Onset Diabetes of the Young: A Case Report. Seminars in liver disease; 2015: Thieme Medical Publishers.
13. Jonasson ME, Wicklow BA, Sellers EA, Dolinsky VW, Doucette CA. Exploring the role of the HNF-1α G319S polymorphism in β cell failure and youth-onset type 2 diabetes: Lessons from MODY and Hnf-1α-deficient animal models. Biochemistry and Cell Biology. 2015;93(5):487-94.
14. Knebel B, Mack S, Haas J, Herman-Friede MK, Lange S, Schubert O, et al. Divergent phenotypes in siblings with identical novel mutations in the HNF-1α gene leading to maturity onset diabetes of the young type 3. BMC medical genetics. 2016;17(1):36.
15. Bahmani M, Sarrafchi A, Shirzad H, Rafieian-Kopaei M. Autism: Pathophysiology and promising herbal remedies. Current pharmaceutical design. 2016;22(3):277-85.
16. García-Ramírez M, Turch M, Simó-Servat O, Hernández C, Simó R. Silymarin prevents diabetes-induced hyperpermeability in human retinal endothelial cells. Endocrinologia, diabetes y nutricion. 2018;65(4):200-5.
17. Rahimi R, Karimi J, Khodadadi I, Tayebinia H, Kheiripour N, Hashemnia M, et al. Silymarin ameliorates expression of urotensin II (U-II) and its receptor (UTR) and attenuates toxic oxidative stress in the heart of rats with type 2 diabetes. Biomedicine & Pharmacotherapy. 2018;101:244-50.
18. Green BD, Irwin N, Duffy NA, Gault VA, O'Harte FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. European journal of pharmacology. 2006;547(1-3):192-9.
20. Musavi-Ezmareh SF, Mazani M, Heidarian E, Alipanah-Moghadam R, Rafieian-Kopaei M, Ebrahimi M, et al. Effect of hydroalcoholic extract of Chevil (Ferulago angulata) on glucose and lipid in diabetic male rats. Iranian Journal of Endocrinology and Metabolism. 2015;17(3):230-7.
21. Hosseinpour Feizi M, Saed S, Babaei E, Montazeri V, Halimi M. Evaluation of Nucleostemin Gene Expression as a New Molecular Marker in Breast Tumors. Journal of Kerman University of Medical Sciences. 2012;19(2).
22. Yuan JS, Reed A, Chen F, Stewart CN. Statistical analysis of real-time PCR data. BMC bioinformatics. 2006;7(1):85.
23. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biological Research. 1994;27:105-.
24. Soto CP, Perez BL, Favari LP, Reyes JL. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology. 1998;119(2):125-9.
25. Stockinger L, Trost W, Uebel H. Quantification électronique des lésions hépatiques experimentales, mises en évidence en histologie. Arch Anat Cytol Pathol. 1976;24:203-9.
26. Soto C, Recoba R, Barron H, Alvarez C, Favari L. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology. 2003;136(3):205-12.
27. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochemical journal. 1988;256(1):205-12.
28. Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta medica. 1989;55(05):420-2.
29. Utrilla M. Natural products with hepatoprotective action. Methods and findings in experimental and clinical pharmacology. 1996;18:11-2.
30. Malekinejad H, Taheri-Brujerdi M, Janbaz-Acyabar H, Amniattalab A. Silymarin regulates HIF-1α and iNOS expression in the brain and gills of hypoxic-reoxygenated rainbow trout Oncorhynchus mykiss. Aquatic Biology. 2012;15(3):261-73.
31. Atawia RT, Mosli HH, Tadros MG, Khalifa AE, Mosli HA, Abdel-Naim AB. Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB. Naunyn-Schmiedeberg's archives of pharmacology. 2014;387(12):1131-40.
32. Jin Y, Zhao X, Zhang H, Li Q, Lu G, Zhao X. Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1α-iNOS following rat lung ischemia-reperfusion injury. Experimental and therapeutic medicine. 2016;12(2):1135-40.
33. Locke JM, Saint-Martin C, Laver TW, Patel KA, Wood AR, Sharp SA, et al. The Common HNF1A Variant I27L is a Modifier of Age at Diabetes Diagnosis in HNF1A-MODY Individuals. Diabetes. 2018:db180133.
34. Haliyur R, Tong X, Sanyoura M, Shrestha S, Lindner J, Saunders DC, et al. Human islets expressing HNF1A variant have defective β cell transcriptional regulatory networks. The Journal of clinical investigation. 2018;129(1).
35. Ozsu E, Cizmecioglu FM, Mutlu GY, Yuksel AB, Calıskan M, Yesilyurt A, et al. Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus. Hormone research in paediatrics. 2018:1-9.
36. Najmi LA, Aukrust I, Flannick J, Molnes J, Burtt N, Molven A, et al. Functional investigations of HNF1A identify rare variants as risk factors for type 2 diabetes in the general population. Diabetes. 2017;66(2):335-46.

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2021 CC BY-NC 4.0 | New Cellular and Molecular Biotechnology Journal

Designed & Developed by : Yektaweb